Latest Signals

New registry results disclosure of previously reported randomized trial. The older Phase 2b result shows a modest every-two-week benefit; the four-week regimen and companion Phase 3 primary test were negative. ClinicalTrials.gov · NCT05037929; full notes.

Primary trial-registry recruitment/start confirmation; no results. The tirzepatide-to-zenagamtide study resolves its elapsed October start estimate, while remaining a small uncontrolled tolerability study. ClinicalTrials.gov · NCT07868354; full notes.

New randomized Phase 2a human protocol; no results. A liver-targeted THRβ agonist will be tested for MRI-measured liver-fat reduction; fibrosis and clinical benefit remain separate questions. ClinicalTrials.gov · NCT07878091; full notes.

Prospective human screening protocol; no results. A Netherlands study plans to evaluate one-time breast MRI in 2,628 women aged 45, measuring cancers detected, tumor size, cost and participant experience. ClinicalTrials.gov · NCT07878377; full notes.

New randomized crossover phase 1/basic-science human protocol; no results. A planned 80-person study will measure simulated driving and behavioral impairment through 24 hours after psilocybin, compared with placebo and alcohol conditions. ClinicalTrials.gov · NCT07877987; full notes.

Registered randomized, outcome-assessor-masked phase 3 protocol in China; no controlled efficacy results. A new 146-person trial plans to compare intratympanic autologous circulating extracellular vesicles plus glucocorticoids with glucocorticoids alone in severe acute sudden sensorineural hearing loss. ClinicalTrials.gov · NCT07878559; full notes.

New original human-trial registration; no results. A planned 100-participant split-wound comparison will test silk dressing against Prineo or paper tape after abdominal surgery. NCT07878390; full notes.

Registry withdrawals; no treated-patient safety or efficacy result. AFN50 and a distinct autologous CD19/BCMA study now record zero enrollment; withdrawal reasons do not establish toxicity or platform-wide failure. ClinicalTrials.gov · NCT07448298; full notes.

Registry status update; not a clinical-hold resolution. The 21-person YTB323 study records September completion; no results or verified lifting of the wider autoimmune hold follows. ClinicalTrials.gov · NCT05798117; full notes.

Phase 3 registration; not yet recruiting. A 2,136-person trial will test ensifentrine on top of maintenance inhalers for moderate or severe COPD exacerbations. ClinicalTrials.gov · NCT07874815; full notes.

New registry results disclosure of previously reported randomized trial. The older positive trial gains detailed efficacy and safety tables, without reversing its companion trial failure or program discontinuation. ClinicalTrials.gov · NCT04701983; full notes.

New Phase 1 randomized human protocol; no results. PF-08656795/MET-815i adds a 150-person dose-escalation protocol focused on safety and exposure, rather than a new weight-loss result. ClinicalTrials.gov · NCT07876518; full notes.

New randomized behavioral-treatment protocol; no results. The 140-person cancer-survivor trial measures insomnia severity/remission and follows durability, fatigue and quality of life. ClinicalTrials.gov · NCT07876661; full notes.

Investigator announcement of an actual development milestone, with live phase 2/3 protocol; no efficacy result. API-2 is testing donanemab, nivagacetor and their combination in PSEN1 E280A carriers. The registered primary outcomes concern amyloid removal and maintenance, so first randomization does not demonstrate dementia prevention. GlobeNewswire · news release; full notes.

Official UK safety-communication action following expert and patient review; not a new treatment trial or a new U.S. warning. UK leaflets will make suicidal-thought/behavior warnings more prominent and name post-SSRI sexual dysfunction explicitly for selected medicines. The change clarifies known risks; it does not supply a new reliable incidence estimate. gov.uk · news release; full notes.

Peer-reviewed single-arm phase 2 follow-up; results previously presented in conference form. Long-term survival after perioperative nivolumab/ipilimumab was encouraging, but the authors found no clear survival improvement over outcomes reported with surgery alone in other studies. JAMA Network · article; full notes.

Registered prospective implementation pilot; no clinical-benefit results. Columbia registered a 55-person pilot of primary-care decision support for hereditary breast/ovarian cancer testing, with an actual September 1 study start. ClinicalTrials.gov · NCT07876349; full notes.

New Phase 1 trial registration; recruitment pending. BMS-986553 plans a 60-person safety-first study in refractory autoimmune disease; no patients or results are verified. ClinicalTrials.gov · NCT07873931; full notes.

Dated sponsor development announcement reconciled with October 16 trial records; no efficacy readout. SUNRISE advances beyond registration, while both live protocols still list recruitment pending and November starts. A maintenance-dosing wording error is explicitly corrected. ir.vikingtherapeutics.com · source page; full notes.

Sponsor-reported initiation milestone plus original Phase 2/3 registry; no new efficacy result. Pelage confirms first dosing in its large pattern-hair-loss trial and forecasts a separate women's Phase 2 study by year-end. Pelage October 14 AWAKEN first-dose announcement; full notes.

Trial-registry update. Forazapadin (SAT-3247) adds a planned randomized trial in inherited FSHD, measuring muscle force as well as safety. This is separate from GLP-1 muscle preservation; recruitment has not begun. ClinicalTrials.gov · NCT07872306; full notes.

Trial-registry update. A randomized osteoporosis study now records actual primary completion. It tests adding abaloparatide to ongoing denosumab using bone-density outcomes; fracture benefit is not established. ClinicalTrials.gov · NCT04467983; full notes.

Trial-registry update. SUPRA-COPD plans a randomized test of urolithin A added to pulmonary rehabilitation, with exercise endurance primary. Strength and lean mass are separate secondary outcomes; there is no efficacy result. ClinicalTrials.gov · NCT07871357; full notes.

Trial-registry update. A newly registered inhaled-cell study in COPD has no randomized comparator or results. Safety and clinically significant changes are primary; registry listing does not validate lung regeneration. ClinicalTrials.gov · NCT07871890; full notes.

Trial-registry update. A 16,390-person randomized shingles-vaccine trial will directly test cardiovascular events in adults with established disease or multiple risk factors. It is not yet recruiting and does not establish cardiovascular prevention benefit. ClinicalTrials.gov · NCT07872046; full notes.

New Phase 3 human-trial registration; not yet recruiting. Amgen plans 230 adults in an open-label study of successful home self-injection, rather than a comparative weight-loss result. ClinicalTrials.gov · NCT07871409; full notes.

Newly public Phase2 human-study registration; completed earlier, no posted results. A 31-person eight-week combination pilot is now registered; it cannot establish longevity or isolate the shared investigational supplements. ClinicalTrials.gov · NCT07871799; full notes.

Primary trial-registry timing revision; no new lipid or outcome result. The previous September 2026 completion window is superseded by July 2027; the study still primarily assesses adverse events. ClinicalTrials.gov · NCT07223658; full notes.

New human device-study registration; retrospective, no posted results. BELL-001 studied immediate EEG/heart responses in 72 adults; this is not evidence of insomnia remission or restored sleep architecture. ClinicalTrials.gov · NCT07872007; full notes.

New Phase1/2 human-trial registration; earlier actual start, noresults. A 20-person immune-directed pilot tests sleepiness/cataplexy in refractory NT1; it does not establish disease reversal or comparative efficacy. ClinicalTrials.gov · NCT07871006; full notes.

New nonrandomized feasibility-study registration; noresults. A 70-person study will test an ICU day/night care package; REM/N3 measurements are secondary, not proven benefit. ClinicalTrials.gov · NCT07869901; full notes.

New formal human device-study registration; no results. SOARA will test an investigational ovarian blood screen in average-risk postmenopausal women and track invasive follow-up burden. ClinicalTrials.gov · NCT07872644; full notes.

New registration of an ongoing prospective case-control study; no results. A urine VOC biosensor study in never-smokers with existing lung nodules tests diagnostic accuracy rather than population-screening benefit. ClinicalTrials.gov · NCT07871656; full notes.

New formal phase 1/2a trial registration; explicitly not yet authorized to begin. IBO-CARE plans ibogaine versus extended-release naltrexone in OUD; its registry explicitly says the IND has not been filed. ClinicalTrials.gov · NCT07871877; full notes.

New phase 3 randomized human trial registration; no result. Trastuzumab brengitecan will be compared with platinum chemotherapy after checkpoint-based therapy in metastatic urothelial cancer. ClinicalTrials.gov · NCT07869836; full notes.

New phase 2a human trial registration; no result. LUTEON ATLAS plans two lutetium 177 girentuximab regimens in advanced CAIX-expressing clear-cell kidney cancer. ClinicalTrials.gov · NCT07870746; full notes.

Newly registered randomized active-comparator human study; no results. A recruiting 390-person Korean study will compare HU-045 with Xeomin for temporary frown-line improvement; results and U.S. authorization are unverified. Original registry; full notes.

Sponsor-posted randomized registry results; not peer-reviewed. In 49 randomized adults, descriptive 18-week changes do not show a clear additional advantage for an unnamed brightening toner over placebo alongside hydroquinone/sunscreen; formal tests and product identity are missing. Original posted results; full notes.

Peer-reviewed randomized human challenge study. A new full paper reports less moderate/severe ETEC diarrhea with once-daily Travelan, but the primary endpoint is nonsignificant with very wide uncertainty. This is a controlled challenge study, not demonstrated real-world traveler protection. Nature · article; full notes.

Dated sponsor conference-program announcement; no new quantitative readout. October 20 presentations will examine postmenopausal women, hypoxic-burden/blood-pressure response and selected patient-reported outcomes. ir.apnimed.com · news release; full notes.

Peer-reviewed cross-sectional human study; primary abstract appraised, full tables/supplement inaccessible. Preclinical-trial screening data show racial/ethnic p-tau217 differences that require careful calibration, without proving unequal test accuracy or prevention benefit. JAMA Network · article; full notes.

Peer-reviewed retrospective matched case-control study; full primary article appraised. A small matched study associates DPYD/UGT1 A1-guided dosing with fewer serious or grade 3+ toxicities; survival benefit was not assessed. Nature · article; full notes.

Direct investigator interview and accompanying conference report; original slides/full follow-up dataset unappraised. MCO-010 reports sustained low-vision test gains at four years, with follow-up denominator and uncertainty still missing. ophthalmologytimes.com · source page; full notes.

Sponsor report of delivered AAO conference results; not a peer-reviewed full trial report. Remigromig met vision noninferiority to ranibizumab, with more proliferative-retinopathy events and adverse-event discontinuations. merck.com · news release; full notes.

Scheduled regulator workshop; not a trial result or approval. An October 30 meeting will examine evidence and European regulatory pathways for phage therapy, with online participation. EMA · source page; full notes.

Sponsor announcement of FDA device designation; no disclosed prospective clinical-utility result. Natera announced a new multi-cancer screening competitor received Breakthrough Device designation. This is development support, not FDA approval or proof that screening reduces cancer deaths. natera.com · news release; full notes.

Peer-reviewed randomized evaluator-blinded trial plus original posted results; Galderma funded. A 192-participant comparison reports visible wrinkle improvement through week 32, with common injection reactions and limited rare-harm precision. DOI · 10.1097/DSS.0000000000005381; full notes.

New registration of an ongoing early device study; no outcomes posted. A ten-person NMS-01 pilot studies blood-brain barrier opening and short-term safety, not established memory preservation. ClinicalTrials.gov · NCT07869238; full notes.

New randomized human phase 2 registration; no efficacy results. PEACE will test feasibility and tolerability of early estradiol after sexual assault; PTSD prevention is not established. ClinicalTrials.gov · NCT07868536; full notes.

Trial-registry recruitment update. The open-label phase 3 extension now lists 455 actual participants and active-not-recruiting status. It primarily assesses longer-term safety and does not yet establish chronic-pain efficacy or approval. Primary registry; full notes.

New human phase 3 trial registration. Pfizer’s 1,100-person randomized study will assess yearly asthma exacerbations. The antibody targets IL-4, IL-13 and TSLP; results in another inflammatory disease do not prove asthma benefit. Primary registry; full notes.

New formal randomized human-trial protocols; not yet recruiting. Two 68-week oral VK2735 trials are registered, each planning 560 participants, with and without type 2 diabetes. ClinicalTrials.gov · NCT07868835; full notes.

New phase 1 open-label human-trial registration. A planned 60-person study examines adverse events after switching; it is not a head-to-head efficacy comparison. ClinicalTrials.gov · NCT07868354; full notes.

Sponsor-reported FDA approval corroborated by approved U.S. prescribing information; FDA letter not independently retrieved. WELTRUZA is approved for adult schizophrenia; approval is distinct from the launch expected in coming weeks. Teva announcement; full notes.

Sponsor conference poster and supplemental slides; selected Phase 3 extension analysis. At week 76, 92.7% of 96 prior 4-mg responders retained the scalp-response threshold. This is not the response rate in all trial participants; serious infections and other adverse events are reported. Original poster and supplement; full notes.

Primary Phase 3 registration plus dated sponsor development statement; no U.S. results. The matched U.S. AURORA denifanstat protocol is now public and recruiting, moving beyond the earlier unmatched trial plan; actual first dosing remains unverified. Original AURORA registry; full notes.

New Phase 2 human registration; no results. A planned 22-person study will add patient-derived gingival-cell vesicles to a standard scaffold/membrane comparison; imaging bone fill is distinct from long-term tooth survival. Original registry; full notes.

FDA approval supported by randomized phase 3 disease-free survival evidence; historical trial results contextualize the new approval. The October 8 approval expands postoperative recurrence prevention for a defined colon-cancer subgroup. ATOMIC improved disease-free survival, with more grade 3/4 toxicity; overall-survival benefit is not established by the FDA summary. FDA · regulatory information; full notes.

Sponsor-only randomized phase 2 topline. Argenx reports a primary histology endpoint success in 126 adults with celiac disease during a controlled gluten challenge. Magnitude, confidence intervals and quantitative harms are not disclosed; this is not a cure or permission to abandon a gluten-free diet. Original October 8 release; full notes.

Sponsor-reported phase 3 recruitment milestone. Saol reports BEACON enrollment completed October 2 across more than twenty U.S. sites. The perineural non-opioid injection is being tested for knee-osteoarthritis pain; no new efficacy or cartilage-repair result is disclosed. October 8 original sponsor release; full notes.

New human phase 3 trial registration. A 148-person Hospital for Special Surgery trial compares suzetrigine with placebo after total knee replacement. Its primary endpoint is 48-hour opioid consumption, with pain and recovery assessed separately; no outcomes are available. Primary registry; full notes.

Dated sponsor regulatory-filing announcement; review, not approval. A potential non-diabetic CKD indication is now under FDA review, based on the already reported FIND-CKD trial. Primary source 1; full notes.

Peer-reviewed observational germline sequencing cohort; official journal and investigator reporting appraised. A single-center 39,184-person cancer cohort found pathogenic variants in 16.3%; a simple under-50 cutoff would miss most carriers. AACR study report; full notes.

New Phase 3 trial registration; no results. A planned 174-person placebo-controlled Chinese trial will evaluate 52-week facial/body repigmentation and patient ratings. It is not yet recruiting. Original registry; full notes.

New trial registration; no results. A planned 176-person vehicle-controlled trial will test a twice-daily biological spray, including adolescent participants and a short off-treatment follow-up. Original registry; full notes.

Peer-reviewed human-trial protocol plus original registry; no results. A75-person adolescent trial will compare single/repeated P11-4 plus fluoride with fluoride alone; the published primary endpoint differs from the registry and does not demonstrate new enamel replacement. Full protocol; full notes.

New randomized human phase 2 trial registration. A planned 400-person trial compares RSV vaccine strategies in two transplant populations. Antibody response is primary; prevention of serious RSV disease and durable safety remain unanswered. Primary registry; full notes.

Sponsor-only topline from randomized double-blind placebo-controlled human trial. At 28 weeks, petrelintide weight loss ranged from 7.4% to 9.2% versus 2.0% with placebo. Dose mapping and confidence intervals remain unreleased. Primary source 1; full notes.

Sponsor statement corroborated by recruiting registries; no efficacy results. Three phase 3 weight-management trials now recruit across non-diabetic obesity, type 2 diabetes and established cardiovascular disease. Primary source 1; full notes.

Sponsor-only small open-label single-dose human data plus scheduled primary conference abstract. Seven paired samples show increased urinary PC1 after one dose; repeat-dose confirmation and kidney outcomes remain pending. Primary source 1; full notes.

Sponsor-funded secondary analysis of randomized NHS-Galleri data; national impact is modeled. Emergency diagnoses were 225 versus 286 across all cancer types; fewer emergencies do not establish reduced mortality. Original EDCC poster; full notes.

Sponsor-funded descriptive conference subgroup analysis. Specificity is high across reported groups, but small cancer counts produce wide sensitivity intervals. Original health-equity poster; full notes.

Sponsor-funded uncontrolled retrospective insurance-claims analysis. Mammography use was 82.2% before versus 83.6% after testing in a selected continuously insured sample. Original mammography-adherence poster; full notes.

Sponsor-funded descriptive categorization of cancers detected in two existing trials. The 204 figure counts site-plus-histology combinations among detected cancers; it is not per-type sensitivity. Original spectrum poster; full notes.

Randomized phase 2/3 trial publication; primary investigator release appraised, full paper inaccessible. Adding local radiation or surgery to first-line systemic therapy did not improve PFS or overall survival in this defined setting. Investigator report; full notes.

Two new early-phase human trial registrations; no patient results. ACE723 and REGN13089-M404-M2980 have planned safety-focused studies in advanced cancer. ACE723 registry; full notes.

New human pilot registration; no results. A planned 10-woman within-person trial will test a naringenin/beta-carotene/menthol cream; no fat-volume or smoothing benefit is established. Original registry; full notes.

New human trial registration; no outcomes. A planned 40-man randomized comparison will assess six-month hair counts; the new record supplies no efficacy or safety result. Original registry; full notes.

Sponsor-reported commercial launch; underlying trial results are older. The cartilage-repair implant becomes available in selected European countries; its five-year paper was published in April, not October. smith-nephew.com · news release; full notes.

Sponsor-funded post hoc statistical modeling of randomized screening data. Modeled detection windows are roughly 1–2 years; this is not a trial comparing screening intervals. Original detection-window poster; full notes.

New formal randomized phase 2 human trial registration. The three-arm trial studies vaccine, PSMA×CD3 bispecific antibody and their combination after biochemical recurrence. Original registry; full notes.

New formal phase 2 human trial registration. Thirty planned participants will receive a labyrinthin-targeted vaccine plus GM-CSF and pembrolizumab. Original registry; full notes.

Official investigator announcement of planned prospective human implementation research. The program will follow participants for at least 24 months, testing whether identified risks lead to useful care. Official Yale announcement; full notes.

New human phase 3 registration of an already started study. A recruiting study plans 25,000 adults aged at least 60 to test a recombinant RSV vaccine against placebo. Its primary outcome is confirmed RSV lower-respiratory disease; no prevention or safety result is posted. Primary registry; full notes.

New phase 3 trial registration. AMBIENCE will test cardiovascular events rather than weight loss alone. ClinicalTrials.gov · NCT07861100; full notes.

New trial registration. Liver fat is primary; biopsy response is secondary and clinical outcomes remain unproven. ClinicalTrials.gov · NCT07859813; full notes.

New formal observational human-study registration; no results. UMIN000063185 plans 800 Beppu residents age 50–89, comparing usual care, digital cognition, blood pTau217/Aβ42, and hierarchical pathway against specialist CDR/amyloid PET. Preinitiation, despite elapsed September 6 estimated start; diagnostic accuracy rather than preventive benefit. Original UMIN record; full notes.

Sponsor conference-schedule announcement; not results. AAO Remain RP PA044 Oct 11 11:42–11:49 AM CT; dry AMD direct-to-phase 2 RCT poster PO624 on demand. These are separate populations; actual Oct 4 GA and BEST1 readouts still unappraised. nanostherapeutics.com · source page; full notes.

Peer-reviewed randomized diagnostic-disclosure trial; full primary article appraised. Earlier p-tau217/NfL disclosure improved clinicians' diagnostic confidence and changed care plans, without established cognitive or functional benefit. JAMA Network · article; full notes.

Official regulatory request for information; not approval or efficacy evidence. FDA seeks public comments on early ibogaine trial design, including cardiac and neurological safeguards, by November 20. FDA · announcement; full notes.

Peer-reviewed journal pre-proof; primary indexed abstract appraised, full article inaccessible. Early Check identifies MECP2 variants in newborns and adult relatives, underscoring that a pathogenic variant is not a guaranteed future phenotype. sciencedirect.com · article; full notes.

New formal randomized human neuromodulation trial registration. The 108-person trial compares focused seizure therapy with two conventional ECT approaches, including memory and quality-of-life outcomes. Original registry; full notes.

Sponsor-reported open-label extension and conference data. HOPE-3 delayed-start participants declined 0.49 PUL points in their treatment year versus 2.05 in their earlier placebo year; the modeled difference was 1.56 points (95% CI 0.47–2.64). The second year was uncontrolled, with incomplete follow-up; this is DMD-specific functional evidence, not general muscle building. Original sponsor report; full notes.

New human phase 3 registration. A planned 700-person masked trial compares CHF5993 triple inhaler with Seretide in adolescents. Its primary endpoint is lung function at week 26; exacerbations, remission and long-term benefit require separate assessment. Primary registry; full notes.

Sponsor-only randomized phase 3 topline and SEC-filed slides. OPUS-1 dosed 4,047 adults. All prespecified primary immune-response comparisons passed, but serotypes 3 and 12F missed the stricter individual Capvaxive noninferiority margin. These are immune responses, not measured prevention of pneumonia or death. Original sponsor release; full notes.

New human phase 2b registration. A 40-person open-label study plans direct-joint antimicrobial dosing for prosthetic-joint infection. Acute groups compare dosing schedules; a separate chronic cohort is uncontrolled. No cure or safety result is available. Primary registry; full notes.

Newly posted registry; actual start predates registration. The trial measures screening completion and diagnosis, not kidney-failure prevention. ClinicalTrials.gov · NCT07857200; full notes.

Registry recruitment/actual-start update. New human adherence study has an uncontrolled registered design. ClinicalTrials.gov · NCT07743931; full notes.

Sponsor announcement of scheduled conference analyses; no new appraised readout. GRAIL announces EDCC October 6–8 and ESMO October 23–27 analyses. Focus on annual preclinical detection windows, race/ethnicity, emergency presentations and diagnostic-workup efficiency/safety; actual effect sizes remain unappraised. October 5 announcement; full notes.

Peer-reviewed prospective randomized diagnostic-strategy trial; retrospective registration. BeSolveRD n 567: genome sequencing 113/284 (39.8%) versus standard exome+copy-number testing 85/283 (30.0%), p=.015. Adjustment for sex/analytical differences reduced advantage to 7.3 percentage points, p=.069. This is symptomatic diagnosis, not healthy-population screening or embryo selection. Full primary paper; full notes.

Sponsor-reported 36 month clinical follow-up/conference results; not full peer-reviewed follow-up. PRIMAvera n 38 implanted; at 36 months n 18 efficacy, n 27 safety. Mean +29 ETDRS letters; 14/18 (78%) >=15 letters. Three SAEs after month 12, none device-alone; no new signal claimed. Science Corporation release via Business Wire/AOL; full notes.

Sponsor conference schedule; results not yet appraised. Lilly lists a BRAVE-AA-PEDS presentation covering baricitinib efficacy through 1.5 years and safety with up to 2.5 years of treatment in adolescents with severe alopecia areata. Brittany Craiglow is the lead author. The announcement supplies no new response rates, participant disposition or comparative adverse-event counts, so this remains an upcoming evidence milestone. October 5 official announcement; full notes.

Trial-registry completion update. NCT07224880 now lists a completed prospective U.S. ellacor micro-coring cohort with nine actually enrolled adults aged 30–65. Its named GLP-1 cohort had lost at least 10% of baseline weight. Original registry; full notes.

Trial-registry completion update. NCT07032597 now lists a completed randomized, assessor-masked Phase 3 study in 252 adults at Chinese sites. HArmonyCa Lidocaine is compared with Restylane Perlane Lidocaine for midface-volume correction, with an optional touch-up. The primary effectiveness measure is at least one grade improvement on the Mid-Face Volume Deficit Scale at month six; adverse events are also primary outcomes. Original registry; full notes.

New study registration; no results. NCT07856797 plans an uncontrolled study of RADIESSE for moderate-to-severe nasolabial folds in 163 Chinese adults, with optional touch-up and up to 24-month follow-up. The primary endpoint is at least one WSRS grade improvement in both folds at month six after final treatment. It is not yet recruiting; start October 2026, primary completion August 2027 and final February 2029 are estimates. Original registry; full notes.

Retrospective Phase 1/2 trial disclosure; no results. NCT07859358, Assiut University, discloses a completed randomized participant-masked Phase 1/2 study in 24 adults with Stage II periodontitis. Scaling/root planing is paired with injectable platelet-rich fibrin, peroxoborate oxygen-releasing gel or saline control. Planned primary measures are clinical attachment, pocket depth and bleeding through 12 weeks. Original registry; full notes.

Peer-reviewed prospective newborn-screening implementation cohort; full primary article appraised. MLD pilots identified nine infants and enabled early care, with five actually treated and incomplete long-term outcomes. Springer · article; full notes.

Peer-reviewed long-term extension; full HTML appraised. Among selected prior baricitinib responders, approximately 85% maintained at least 80% scalp coverage at week 200; long-term serious harms were uncommon but occurred, without a continuing placebo comparison. Full primary paper; full notes.

Peer-reviewed randomized sham-controlled trial; accepted early article and abstract. LoRD-KNeA randomized 114 people with knee osteoarthritis. The 3 Gy group had more four-month responders than sham, but the difference was no longer significant at 12 months; continuous pain/function and MRI measures did not differ significantly. Published abstract; full notes.

Sponsor-reported phase 2 extension and conference data. AMETHYST reports clear/almost-clear skin in 27.2% of participants initially assigned litifilimab at week 52. All groups received active treatment after week 24, so extension responses are not a new placebo comparison. October 2 sponsor report; full notes.

Peer-reviewed within-scar comparative trial; full HTML appraised. A 16-person study favored injected botulinum on pliability, but the overall scar-score comparison was p=.051, and fixed section assignment weakens its randomized claim. Original full publication; full notes.

Sponsor regulatory announcement, syndicated original release. Biosplice reports EMA validation on September 30, resolving the elapsed filing forecast. Administrative validation starts review; it is not approval or new proof of cartilage repair, pain relief or avoided replacement. Syndicated original sponsor release; full notes.

New human phase 1 registration. A recruiting single-arm study plans eight participants up to age 25 with refractory childhood-onset lupus. The primary outcome is low disease activity at one year; no results or safety rates are posted. Primary registry; full notes.

New phase 4 human-trial registration. A planned 48-person placebo-controlled trial will assess seven-day pain, opioid use and tolerability alongside standard multimodal analgesia. It is not yet recruiting and has no results. Primary registry; full notes.

New randomized screening-management trial registration. Primary outcome is 90-day treatment change, with patient outcomes still prospective. ClinicalTrials.gov · NCT07853716; full notes.

Sponsor presentation announcement. Concrete ASN presentation catalyst; results not yet appraised. GlobeNewswire · news release; full notes.

New phase 3 trial registration. The 1,500-person plan prioritizes safety and noninvasive liver measurements. ClinicalTrials.gov · NCT07854782; full notes.

Sponsor-reported EADV observational cross-sectional survey. SCOP-GLP1 surveyed 5,804 people in France, the U.S., Mexico and Brazil: 575 GLP-1 users, 1,329 unexposed people with type 2 diabetes and/or overweight, and 3,900 reference participants without those conditions or exposure. Reported hair loss was 65.2% in GLP-1 users versus 35.3% in metabolic controls; 53.9% versus 26.5% sought hair-related care. These are self-reported proportions, not prospective adverse-event incidence. Sponsor survey report; full notes.

Retrospective clinical-trial disclosure; no results. NCT07854470 describes topical ON101 after lower-extremity fracture fixation in 30 adults: 20 receiving ON101 and 10 standard care, with Vancouver Scar Scale and photographic measures through 16 weeks. No results are posted. The narrative describes a prospective evaluator-masked controlled study, while structured design fields say single group and no masking; dates in the narrative also differ from structured actual dates. Original registry; full notes.

New human study registration; no results. DEFINE (NCT07855224) is a planned prospective, uncontrolled post-market follow-up of calcium-hydroxylapatite Facetem S for moderate-to-severe nasolabial folds. It plans 100 adults, with France/Spain sites, optional touch-up and follow-up to 12 months. The primary endpoint is at least one WSRS grade of improvement at week 12, or week 16 after touch-up. Original registry; full notes.

Official conference randomized-study abstract; full paper not appraised. A 45-person randomized post-orthodontic white-spot-lesion study compares P11-4, fluoride varnish and no treatment in adults aged 18–30, followed six and twelve months. The abstract reports a fluorescence ΔF advantage over varnish (p<.001), but no P11-4-versus-varnish ICDAS difference, and no lesion-area advantage over untreated controls. Its own conclusion says visible masking was similar. Official abstract; full notes.

Original trial-registry status update; no efficacy results. The October 2 record lists the planned 600-person Phase 2/3 study as recruiting and records September 21 as the actual study-start date. This supersedes the prior not-yet-recruiting snapshot; it does not independently verify first dosing or earlier rumored emails/dates. Primary completion remains estimated for December 2027, final completion June 2028; public result timing is unannounced. AWAKEN record; full notes.

EASD conference report reproduced by sponsor; exploratory human subgroup. Caliway posted the EASD press-room report on October 2 after the September 30 presentation. A pooled MRI subgroup from CBL-0204/0205 included 41 people at baseline (23 CBL-514, 18 placebo) and 40 with late follow-up (23, 17). At four weeks after final treatment, visceral-fat volume changed −12.01% versus +5.68%; at the pooled 8–12-week follow-up, −10.45% versus +11.76%. Small selected pooled subgroups and short follow-up do not establish durable metabolic or cardiovascular benefit; weight-regain findings remain animal evidence. Caliway EASD human visceral-fat subgroup report; full notes.

Sponsor commercial-launch announcement and Health Canada product record; no new comparative trial. Canada gains an escitalopram oral-solution brand; this is a formulation/access update, not a new SSRI mechanism or proven better tapering. newswire.ca · news release; full notes.

Sponsor-reported randomized phase 2 results; conference presentation; publication described as in press. At 52 weeks, DXA lean mass changed −7.3% with semaglutide plus placebo, −5.8% with trevogrumab 25 mg and −4.2% with 75 mg. The new low-dose portion is separate from the previously reported high-dose triplet. October 1 sponsor report; full notes.

Peer-reviewed single-centre phase 2 proof-of-principle randomized double-blind placebo-controlled trial. Dasatinib plus quercetin improved fibrosis in 8/17 versus 1/14 participants at 21 weeks. This is an early disease-specific signal, not proof of cure or longer life. Primary source 1; full notes.

Peer-reviewed randomized placebo-controlled mechanistic trial. New kidney paper retains primary null results and a discontinuation imbalance. Nature · article; full notes.

Peer-reviewed systematic review and meta-analysis of human screening cohorts. Across 17 heterogeneous low-quality studies (18,043 total), malignancy yield was 1.4% (95% CI 0.9–2.2%) in 4,463 participants with pathology-confirmed reporting; downstream clinical outcomes, false positives and overdiagnosis could not be determined. Full primary review; full notes.

Peer-reviewed critical appraisal and reanalysis of three network meta-analyses. Removing n 40 fluoxetine–nortriptyline outlier reduces combined fluoxetine–placebo estimates from SMD -.51 to -.26 (95% CrI -.43, -.09)/-.29 (-.50, -.07). Benefit remains statistical but smaller; authors judge small clinical importance. Pediatric depression only, no approval/guideline change. Full primary paper and Table 4; full notes.

Sponsor-reported foreign regulatory filing milestone. PMDA acceptance/priority review for MOGENRY/MCO-010 seeking IRD indication; distinct US FDA filing for RP severe vision loss under review. No approval, GA indication or new controlled clinical result. October 1 original release; full notes.

Trial registry timing revision. The October 1 update to NCT07032038 moves Rincell-1's estimated study start from November 2026 to September 2027, and estimated primary completion from July 2028 to May 2029; final completion is now estimated for August 2029. The phase 1/2 study remains not yet recruiting, with 20 planned adults eligible for cochlear implantation. It compares an implant plus otic neural progenitor cells with an implant alone. ClinicalTrials.gov · NCT07032038; full notes.

Sponsor announcement; blinded trial progress and exploratory pilot. Syntara is expanding the phase 1b SNT-9465 topical pan-LOX-inhibitor study of hypertrophic sternotomy scars from 20 to 30 participants and adding The Skin Hospital in Sydney. Initial recruitment is only nearing completion, so the earlier Q3 target should not be marked achieved. Active-versus-placebo comparisons within scars remain blinded; the sponsor says expansion was not driven by efficacy data. Topline is now forecast for Q1 2027. A separate keloid pilot had eight local-reaction discontinuations and no observed clinical improvement at week 12. October 1 sponsor announcement; full notes.

Sponsor-only phase3 extension and randomized substudy. AbbVie reported week-76 Viti-Up1/2 results for non-segmental vitiligo. Among continuously treated observed cases, F-VASI75 facial response was 55.1% and 47.4%; T-VASI50 body response was 42.5% and 40.1%. Week-76 denominators were 127 and 137. These selected extension observations do not retain a randomized placebo comparison; numerical phototherapy separation lacks intervals or significance tests. EADV sponsor release; full notes.

Peer-reviewed phase 2a randomized trial abstract; full text unavailable. Fourteen severe peanut-allergic participants had no significant primary IgE-ratio difference with abatacept versus placebo added to oral immunotherapy. Tolerability signals were exploratory; sustained food-challenge responses did not differ. Primary abstract; full notes.

New randomized trial registration. The planned combination comparison uses a 24-week albuminuria endpoint. ClinicalTrials.gov · NCT07849348; full notes.

New trial registration. A primary proteinuria comparison will precede longer filtration and safety follow-up. ClinicalTrials.gov · NCT07850752; full notes.

Retrospective trial registration; no results. NCT07849205 discloses a completed, uncontrolled U.S. pilot in 12 adults aged 35–65 receiving mechanical microneedling with AnteAGE Exosomes, PEARL Multiplier and a multicomponent home-care regimen. Twelve-week outcomes include skin-retraction time, VISIA coarse-wrinkle area and water loss. Original registry; full notes.

Sponsor-reported randomized phase 2b conference results. NCT06603571 randomized 367 adults with overweight/obesity and type 2 diabetes. At 48 weeks, eloralintide 9 mg plus tirzepatide 15 mg produced 23.3% mean weight loss versus 14.8% with tirzepatide 15 mg and 3.0% with placebo. These are efficacy-estimand estimates assuming continued treatment; placebo comparison was primary and tirzepatide comparison secondary. A1c fell 2.91 versus 2.41 points. Adverse-event discontinuation was 27.0% versus 2.9%; the proposed phase 3 co-formulation has not been tested here. Lilly · news release; full notes.

New phase 2 trial registration. NCT07848880, first posted September 30, plans a 315-person randomized, masked, placebo-controlled study of weekly DR10624 in hypertriglyceridemia with diabetic kidney disease. The primary endpoint is fasting triglyceride percentage change at week 26. Secondary measures include other lipids, urine albumin, eGFR and MRI liver fat through the treatment period. ClinicalTrials.gov · NCT07848880; full notes.

Trial registry update. NCT06926660 now lists actual completion August 14, 2026 and enrollment of 492, in the September 30 record. It compares simultaneous versus staggered vicadrostat/empagliflozin initiation, with short-term eGFR, albuminuria, blood-pressure and potassium measures. No results are posted. ClinicalTrials.gov · NCT06926660; full notes.

Peer-reviewed primary abstract and sponsor publication announcement. Phase 3 open-label evERA (NCT05306340; 373 patients) compared giredestrant plus everolimus against physician-selected endocrine therapy plus everolimus after CDK4/6-inhibitor/endocrine treatment in ER-positive/HER2-negative advanced breast cancer. Median progression-free survival was 8.8 versus 5.5 months overall (HR 0.56, 95% CI 0.44–0.71), and 10.0 versus 5.5 among 207 patients with ESR1 mutations (HR 0.38, 0.27–0.54). Overall survival remains immature; longer survival is not established. Primary paper; full notes.

Sponsor-only preliminary randomized phase 2 topline. Seabreeze STAT COPD (NCT06940154) randomized 159 adults with acute COPD exacerbation and eosinophils ≥300/µL to one rademikibart injection or placebo alongside standard care. Sponsor reports 81% relative reduction in 28-day treatment failure (p=0.0122), a composite of death, COPD rehospitalization/emergency or unscheduled visits, and treatment intensification. Moderate/severe exacerbations fell 85% relatively (p=0.030). Absolute counts, confidence intervals and numerical safety tables were not released; the earlier asthma primary miss remains separate. Sponsor; full notes.

Sponsor-only EADV phase 2a open-label follow-up. Q32 reported 16 weeks off treatment after SIGNAL-AA Part B (NCT06018428). Of 33 originally treated adults with severe/very severe alopecia areata, 18 entered off-drug follow-up; 44% had SALT ≤20 at week 52. Among the selected 12 with hair growth at week 36, all met the maintenance definition: less than a 20-point SALT worsening from their last on-treatment visit. Full notes include study limitations and safety. Sponsor release; full notes.

Sponsor-only open-label extension; prospective phase3 plan. Sagimet reported ASC40-304 (NCT06248008), a 240-participant Chinese extension following a 480-person randomized acne trial. At total study week 52, 56.7% met the composite of clear/almost-clear skin and at least a two-grade IGA improvement; total lesions decreased 71.8% from original baseline. All received active 50 mg daily during the 40-week extension: prior active recipients had 52 weeks of exposure, prior placebo recipients only 40. No concurrent placebo remains during the extension. U.S. AURORA screening is forecast for October, with initiation unverified. September 30 sponsor release; full notes.

Sponsor-only randomized Phase 3 topline, recovered October 16; not newly released today. The diary-based treatment difference was 37.1 minutes over 28 days; confidence intervals, full harms and analysis of all 43 enrolled remain unavailable. PR Newswire · news release; full notes.

Peer-reviewed randomized Phase 2 primary abstract; full supplement unreviewed. The September 29 paper supplies dose-specific weight estimates and harms; it is separate from October 7 ZUPREME-2 diabetes topline. PubMed · PMID 42810355; full notes.

New investigator randomized open-label comparative-effectiveness protocol; no results. TIRZE-PAP plans a 256-person comparison using repeated home breathing-disturbance monitoring, not a completed demonstration that drugs replace PAP. Primary source 1; full notes.

Peer-reviewed phase 3 primary abstract; full-text access gap. New publication of the existing trial adds diagnosis-specific OSA and OA evidence. PubMed · PMID 42814954; full notes.

Peer-reviewed primary abstract plus sponsor conference disclosure. The Lancet report of TRIUMPH-2 (NCT05929079; 1,152 adults with obesity/overweight and type 2 diabetes) reports 80-week treatment-regimen weight loss of 11.9%, 16.8% and 18.8% with retatrutide 4, 9 and 12 mg versus 5.1% with placebo. For 12 mg, the placebo-adjusted difference was −13.8 percentage points (95% CI −15.8 to −11.8). This analysis includes treatment discontinuation; the earlier 20.8% headline is a different, efficacy estimand. Full notes include study limitations and safety. PubMed · PMID 42810372; full notes.

Sponsor-reported regulatory filing acceptance. Genentech reports FDA acceptance and granted Priority Review for oral fenebrutinib in relapsing and primary progressive MS. This is review, not approval. FENhance 1 and 2 reduced annualized relapses versus teriflunomide by 51.1% and 58.5% over 96 weeks. Liver abnormalities and a reported fatality imbalance remain relevant; a review target date was not disclosed. Sponsor; full notes.

Sponsor-reported regulatory submission. DBV announced VIASKIN Peanut BLA submission for peanut-allergic children aged 4–7 on September 29 at 18:29 Eastern. Priority Review was requested; FDA acceptance or granted Priority Review has not been established. The dossier uses VITESSE (NCT05741476), a randomized double-blind 2:1 patch-versus-placebo trial of 654 children over 12 months. Full notes include study limitations and safety. Sponsor; full notes.

Sponsor-only randomized phase 3 topline. LIBERTY (NCT07655180) randomized 210 healthy adults aged 18–49 among VYD2311 250 mg, Comirnaty, or both. Six-day adverse events/injection reactions/hypersensitivity occurred in 56.5% with VYD2311 versus 91.4% with Comirnaty; systemic events occurred in 44.1% versus 68.1%. No VYD2311-related event exceeded grade 2; no arm reported hypersensitivity/anaphylaxis. Full notes include study limitations and safety. Sponsor; full notes.

Sponsor development announcement and primary trial registry. Hengrui and Novo announced development rights for an oral dual agonist intended for weekly dosing; human efficacy is not established. Registry remains NOT_YET_RECRUITING. September 2026 is an estimated start month, not proof of dosing. China permission to initiate research is not marketing approval. Hengrui September 29 announcement; full notes.

Sponsor-reported conference indirect comparison. A new comparison uses separate SURMOUNT-1 and STEP UP trials, not randomization between tirzepatide and semaglutide 7.2 mg. Adjusted for sex, age, initial weight and A1c; residual cross-trial differences remain. Credible intervals are not confidence intervals. Do not present as a new head-to-head trial or add to randomized endpoint plots. Lilly EASD indirect comparison; full notes.

Sponsor-reported conference indirect comparison. A covariate-adjusted indirect analysis compares orforglipron 17.2 mg against oral semaglutide 25 mg in adults with type 2 diabetes. This is not the ACHIEVE-3 randomized comparison against oral semaglutide 14 mg. Cross-study assumptions and treatment-adherent estimands limit causal interpretation. Lilly September 29 oral-drug comparison; full notes.

Sponsor-reported retrospective observational conference analysis. COMPETE SWITCH CV reports an association favoring semaglutide dose escalation among prior semaglutide 1-mg users; it cannot establish drug superiority. Treatment groups differ and the release’s numerical HR presentation needs clarification; no new estimate was added to the clinical-trial plot. Novo-authored UK release with exposure-group counts; full notes.

Sponsor-reported human phase 2 follow-up and phase 3 enrollment, with October9 registry corroboration. Two-year SPECTRA findings are small and uncontrolled; 4SIGHT will compare vision and injection burden against aflibercept. Original sponsor report; full notes.

New registry recovered from overlap search. Registration is now verified; recruitment and clinical benefit remain pending. ClinicalTrials.gov · NCT07843329; full notes.

Professional-society clinical guidance; not a new trial. The September 28 EASL–EASD–EASO guidance addresses selection, initiation, monitoring and stopping of resmetirom and weekly semaglutide 2.4 mg as MASH-targeted treatments. It recommends individualizing choice by metabolic disease, body composition, other conditions and preferences; the strength of the recommendation should not be mistaken for high-certainty comparative evidence. This is an interpretation of existing evidence, not a new randomized head-to-head trial or proof of reduced liver-related deaths. journal-of-hepatology.eu · article; full notes.

Trial registry update. The September 28 ClinicalTrials.gov update lists SPINOZA (NCT07794670) as recruiting, replacing the notebook's not-yet-recruiting snapshot. The planned 400-person, placebo-controlled phase 2 study tests obicetrapib 10 mg daily in preclinical Alzheimer's disease. Its primary outcome is change in plasma p-tau217 at 52 weeks; cognition (PACC5) is secondary. ClinicalTrials.gov · NCT07794670; full notes.

Peer-reviewed systematic review and network meta-analysis; appraisal of previously flagged lead. A September 28 network meta-analysis of 96 randomized trials (18,419 adults) compared six types of digital insomnia intervention. Digital CBT reduced Insomnia Severity Index scores by 4.24 points versus pooled controls (95% CI 3.65–4.83 points lower; moderate certainty), reaching the authors' four-point clinically important threshold. The ISI analysis itself included 72 trials and 14,405 people. Evidence synthesis; full notes.

Peer-reviewed primary abstract; full-text appraisal incomplete. In a prospective study of 25 women, both facial sides received radiofrequency microneedling; the right side received 2 mL Rejuran polynucleotide and the left saline. At six weeks, pore-score improvement was 4.79 versus 0.95 and wrinkle-score improvement 5.04 versus 3.67 (both p<0.001). Dermal-thickness and elasticity differences were not significant. Primary publication abstract; full notes.

Randomized phase 2 conference abstract and investigator-society report. SOFT Preop enrolled 102 people with operable or selected locally advanced pancreatic cancer after chemotherapy; four withdrew. Five SBRT sessions were compared with 28 radiation sessions plus concurrent chemotherapy. This small superiority trial does not establish survival equivalence or noninferiority. Quality-of-life effect sizes and confidence intervals were absent from the available abstract. SBRT included regional nodes; results cannot be generalized to every SBRT regimen. Exact registry ID not verified. ASTRO investigator announcement; full notes.

Sponsor trial-development announcement. Biohaven reports enrollment has begun for its FGFR3 antibody–drug conjugate BHV-1530 plus cemiplimab in advanced solid tumors. The release does not provide new cohort-specific response rates, denominators or comparative survival. Previously disclosed partial responses cannot establish superiority. Biohaven September 28 release; full notes.

Sponsor phase 1 uncontrolled human results. At 12 months, 7/13 evaluable participants met lupus-remission criteria; infections occurred in 13/24 of the safety cohort, including two grade ≥3. Small uncontrolled phase 1 results cannot establish cure or comparative benefit. Adicet September 28 release; full notes.

Conference investigator report; prospective observational cohort. A 20-person treatment-resistant-depression cohort reports improvement after stereotactic radiosurgical capsulotomy, an irreversible lesion-making procedure. No control group or causal attribution. Specialized, highly selected population; two participants lacked depression-score evaluation. ASTRO says its release contains updated author data differing from the original abstract. Reduced ideation is not proven suicide prevention. ASTRO September 28 author-updated study release; full notes.

Sponsor phase 3 randomized topline. Zenkuda/tarcocimab and tabirafusp-ted met vision noninferiority versus aflibercept in treatment-naive wet age-related macular degeneration. Noninferiority is not superior vision. Release omits mean letter gains, confidence intervals and margin; different retreatment schedules prevent a simple matched comparison of maximum durability. Registry still lists a stale 675-person estimate. Kodiak DAYBREAK sponsor release; full notes.

peer-reviewed prospective comparative cohort. A clinician-supervised photo-monitoring pathway plus caregiver education was associated with fewer recorded problems during childhood palate expansion. Nonrandomized self-selection, unequal opportunities to detect transient problems, unmeasured caregiver differences and no adjusted analysis. Education and monitoring cannot be separated. Total visits, whole-course duration, final bite, roots and long-term retention were not established. Original full study; full notes.

Peer-reviewed accepted randomized split-scar trial; abstract-level appraisal. Forty-one participants were randomized; six were lost and 22 discontinued, mainly for wound-related complications. Per-protocol appearance results favor taped scar segments, limiting generalization. Original accepted publication; full notes.

Verified available; posting date unknown. Official conference abstract available before scheduled presentation. The extension reports partial regain of weight, fat and visceral fat after stopping bimagrumab and/or semaglutide. Actual abstract posting date unavailable: September 27 is verification, not publication/presentation date. Follow-up denominators, intervals and missing-data details absent. Prior switching/open-label extension and subgroup comparisons limit causal inference; no proof of lasting muscle function or diabetes remission. EASD 2026 abstract 112; full notes.

New-to-watch in-window human trial registration. FXS5626-VIT-301 (NCT07840820) is a planned Chinese randomized, masked placebo-controlled adaptive Phase 2/3 study in 480 participants aged 12–75 with nonsegmental vitiligo. The design includes 120 dose-ranging participants and 360 in Phase 3. Primary measures are percent change in facial VASI at week 24 and F-VASI75 response at week 52, respectively. Original registry; full notes.

New-to-watch retrospective trial registration; no results. NCT07842120 is a recruiting randomized Phase 2 study of 60 planned participants comparing micro-osteoperforation, local prostaglandin E1, local calcitriol and control. The primary endpoint is mandibular anterior alignment measured by Little's Irregularity Index at six months. It reports an actual April 16 start, predating registration; primary completion December 30, 2026 and final February 2027 are estimates. Original registry; full notes.

Trial registry update. The September 25 record for Vibrance 3 (NCT06843590) lists active, not recruiting, replacing the notebook's earlier recruiting snapshot. This randomized phase 2 study tests alixorexton (ALKS 2680), an orexin-2 receptor agonist, in idiopathic hypersomnia; planned enrollment remains 126. Primary and final completion remain November 2026 registry estimates. Vibrance 3 registry; full notes.

U.S. prescribing information plus dated sponsor approval announcement. FDA approval now includes patients aged 12 and older with severe alopecia areata. The September 2026 U.S. label confirms the expansion; the separately retrieved HTML label still displayed June and should not be used for current eligibility. BRAVE-AA-PEDS randomized 257 adolescents to placebo, 2 mg or 4 mg daily. Full notes include study limitations and safety. Announcement; full notes.

Peer-reviewed cluster randomized trial. An integrated nonpharmacologic perioperative-care strategy reduced opioid exposure but did not improve its coprimary patient-reported outcomes. Stepped-wedge cluster design; procedure count is not unique-patient count. Prescription/administration records are not complete consumption data. Approximately 70% patient-reported response and a predominantly White single-system population limit generalizability. NOHARM randomized clinical trial, JAMA Network Open; full notes.

Sponsor report of foreign regulatory/access milestone. Ocugen reported provisional approval and priority designation from the Bahamas LARTA Board for OCU400 in inherited retinitis pigmentosa. No new efficacy or safety data. An independent Bahamas regulator document was not reviewed; regulatory characterization is sponsor-attributed. Keep inherited retinal disease separate from common acquired vision loss. Ocugen Bahamas provisional-designation release; full notes.

Trial-registry announcement. Nucleus registered NCT07841769, a prospective observational comparison of patients choosing polygenic-score-based versus morphology-based embryo selection. It is not yet recruiting, with about 2,000 participants planned. Families choose their selection strategy; there is no random allocation. This cannot establish long-term offspring disease prevention, intelligence gains, or general clinical utility. Ancestry calibration, available embryo numbers and self-selection remain important limitations. Registry narrative claims about adult/sibling data are not offspring outcomes. Original trial registry; full notes.

Trial-registry update, no results. Both pivotal trontinemab trials now list active-not-recruiting status and actual enrollment. Exact recruitment-closure date is not supplied. Registry posting is the recorded event date. The new TRONTIER 2 estimate supersedes the notebook’s June 7, 2028 estimate; neither is a promised publication date. This is symptomatic treatment, separate from PrevenTRON prevention. TRONTIER 1 registry; full notes.

Peer-reviewed randomized phase 3 final secondary-endpoint analysis; primary abstract appraised. HER2-positive high-risk early breast cancer, n 454, adding atezolizumab did not significantly improve 3 y EFS 91.4 vs 89.0% (HR .90, 95% CI .50–1.59) or DFS 92.9 vs 88.5% (HR .71, .38–1.32); adjuvant special-interest AEs 59.4 vs 47.0%. New paper uses August 2023 cutoff; prior pCR failure remains. Primary abstract; full notes.

Newly recovered trial registration. NCT07839936, first posted September 24, provides the concrete phase 2 plan behind the earlier end-2026 forecast. HEART-3 plans 175 adults with or at high risk for ASCVD who need additional LDL lowering, randomized and double-blind against placebo. The primary endpoint is LDL-C change at day 90; ApoB and other lipids are secondary. ClinicalTrials.gov — HEART-3 first posted September 24, 2026; full notes.

New human trial registration; October 1 registry refresh. KOMET (NCT07839338) was first posted September 24 and refreshed October 1. This Indian phase 3 study plans to randomize 220 adults aged 18–65 with moderate-to-severe major depressive episodes in major depressive disorder or bipolar disorder to adjunct oral ketamine or oral midazolam as an active placebo. Nine supervised sessions are planned; the primary outcome is HAM-D depression severity at week 3, with symptom, response/remission, function and safety follow-up through week 4. ClinicalTrials.gov · NCT07839338; full notes.

Sponsor-only uncontrolled clinical follow-up; recovered September event. Kyverna reported single-arm CD19 CAR-T follow-up in refractory stiff-person syndrome (KYSA-8, NCT06588491; 26 adults) and generalized myasthenia gravis (KYSA-6, NCT06193889; seven patients). In SPS, median timed-25-foot-walk improvement was 49% at 12 months; 92% were off chronic SPS immunotherapies. Only five myasthenia patients had at least one-year follow-up; all seven had week-24 mean MG-ADL and QMG improvements of 8.3 and 11.7 points, and six were off immunosuppression at last follow-up. Sponsor; full notes.

Institutional announcement of planned human research. Fraunhofer and Leicester describe REPhRAME, a five-year European collaboration intended to test bacteriophages for recurrent urinary infections. A Frankfurt-led randomized clinical study is planned to compare phages alone, phages with antibiotics, and phages with gut-microbiota restoration. This is a credible human-stage research plan, not evidence of effectiveness. Full notes include study limitations and safety. Fraunhofer; full notes.

Peer-reviewed randomized trial abstract plus registry; full text not appraised. A September 24 publication reports the previously watched NCT06685029 trial: 52 participants randomized among directly printed aligners, Invisalign, ClearCorrect and fixed appliances. Treatment durations were 6.59±1.42, 5.36±1.63, 5.72±1.88 and 10.16±2.28 months, respectively; the fixed-appliance group took longer than each aligner group (p<0.001). The abstract does not establish direct printing as faster than other aligners. Publication; full notes.

FDA approval and randomized phase 3 evidence. Welireg plus Lenvima is approved for advanced renal-cell carcinoma with a clear-cell component after PD-1/PD-L1 therapy. Final overall survival was not statistically significant: 33.7 versus 28.6 months, HR 0.85 (0.70–1.03). Better PFS does not establish longer survival; this is cancer treatment, not kidney preservation. FDA belzutifan–lenvatinib approval; full notes.

FDA regulatory action. Onswik (insulin efsitora alfa-gobe) adds a weekly basal-insulin option for adults with type 2 diabetes. Approval does not establish superior complication prevention or immediate pharmacy stock. FDA identifies it as the second approved weekly insulin. FDA once-weekly insulin approval; full notes.

Sponsor preliminary open-label and subgroup analyses. Vistagen reported supportive exploratory findings in social anxiety; they do not reverse the randomized PALISADE-4 primary miss announced in June. Uncontrolled OLE, changing denominators and post-hoc subgroup selection limit inference. Some participants had not reached four months at the July cutoff; missing observations are not all treatment discontinuations. Detailed repeat-dose tables were not appraised. Vistagen preliminary PALISADE-4 OLE; full notes.

Sponsor phase 2 randomized topline results. RADIANT’s phase-2 portion missed its primary endpoint despite a nominal secondary signal; Acadia plans continued phase-3 enrollment. Analyses used a prespecified modified population. Sample counts, confidence intervals and complete tables were not disclosed. These outcomes concern hallucinations/delusions, not Alzheimer progression or prevention. Acadia RADIANT phase-2 release; full notes.

Sponsor phase 2b/3 randomized topline results. Both remigromig doses met week-52 visual-acuity noninferiority versus ranibizumab in diabetic macular edema; the safety imbalance is material. No letter-change estimates, confidence intervals, noninferiority margin or absolute adverse-event rates disclosed. Noninferiority does not establish better everyday vision, retinal regeneration or longer dosing intervals. Proliferative diabetic retinopathy, vitreous hemorrhage and adverse-event discontinuations were more frequent with remigromig than ranibizumab. Sponsor says further analyses are underway. Merck BRUNELLO topline release; full notes.

trial-registry registration. A newly registered supplement trial will test biological changes in gray-hair percentage; it has not begun recruiting and has no results. Registration does not establish pigment restoration or efficacy. This is a dietary-supplement study, not a Phase 3 drug program. The title says triple-blind while structured masking fields say quadruple; no inference about completed masking or enrollment. Results must distinguish newly pigmented growth from changes in overall hair counts. Primary study record; full notes.

Peer-reviewed phase 2 publication; recovered September report. The September 23 Explore-CKD paper reports a randomized masked crossover trial in 59 adults with uncontrolled hypertension, CKD and albuminuria. Lorundrostat 25 mg daily was added to SGLT2 inhibition and ACE-inhibitor/ARB background treatment. Four weeks of treatment lowered office systolic blood pressure by 7.5 mmHg versus placebo; albuminuria also fell. PubMed · PMID 42778148; full notes.

FDA advisory-committee record. Panel votes favored safety 10–0, effectiveness 6–4, and benefit versus risk 7–2 with one abstention. Nonbinding advice is not FDA approval. Members questioned early-detection wording and limited stage I performance. Mortality benefit, overdiagnosis and optimal testing intervals remain unresolved; standard cancer screening should continue. FDA 24-hour panel summary; full notes.

FDA approval with single-arm evidence. Lyrfigtu is approved for previously treated unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement. Open-label single-arm evidence cannot establish comparative survival benefit. Keep this molecularly selected cancer population distinct from unselected bile-duct cancer. FDA lirafugratinib approval; full notes.

Peer-reviewed uncontrolled phase 1 study. Among 38 infused patients with heavily pretreated relapsed/refractory myeloma, all responded; 30/38 had complete responses. Small uncontrolled dose study; neither complete response nor survival estimates establish cure or superiority to another CAR-T. Laboratory binder comparisons are not a clinical head-to-head trial. All 38 had adverse events and 37/38 grade ≥3 events. At the recommended dose, 94% had grade 1/2 cytokine-release syndrome; none grade ≥3. ICANS included one grade 3 event. No delayed/non-ICANS neurotoxicity observed does not exclude rare risks. NEJM anito-cel primary publication; full notes.

Sponsor Phase 3 interim topline. IMAgINATION met its 37-week urine-protein endpoint; clinical kidney-function follow-up remains pending. No effect magnitude, confidence interval, p-value or analyzed interim denominator disclosed. Proteinuria reduction does not establish fewer dialysis, transplant or kidney-failure events. Roche September 23 IMAgINATION announcement; full notes.

Sponsor topline randomized human trial. Immunovant stopped IMVT-1402 development for cutaneous lupus after its phase 2 proof-of-concept trial missed the primary endpoint. No effect size, confidence interval or p value disclosed. Numerical trends and IgG associations do not overturn the primary miss. The August 28 registry snapshot remains active-not-recruiting and is stale relative to the discontinuation announcement. Immunovant CLE topline announcement; full notes.

Sponsor phase 2a follow-up. EVERLAST-A reported sustained skin clearance 24 weeks after the second ORKA-001 dose. There is no contemporaneous untreated comparator after crossover. These sponsor data do not establish annual dosing, cure, or long-term safety. Oruka EVERLAST-A week-28 release; full notes.

Sponsor operational milestone. Actinogen reported the final XanaMIA participant visit on September 22 in the U.S.; results remain expected in November. Visit completion is not a positive efficacy result. The announcement provides no final treatment-effect or safety results; the registry identifier was not independently matched during this run. Actinogen XanaMIA final-visit announcement; full notes.

sponsor development announcement; registry cross-check. Caliway reports that its pivotal abdominal-fat study has entered treatment, beyond the earlier recruitment announcement. September 23 is the announcement date; the exact first-dose day is undisclosed. Treatment initiation supplies no Phase 3 efficacy result. Two-grade patient/clinician improvement is assessed separately from MRI fat-volume change. The same release’s new semaglutide/eloralintide combination findings are preclinical, not human weight-regain evidence. Caliway first-dose announcement; full notes.

Sponsor-submitted registry results; newly appraised older source. The September 22 results record reports adverse events in 22/51 active versus 10/27 vehicle participants. It does not supply a numerical controlled hair-regrowth outcome. Original results record; full notes.

Regulator briefing; verified September 22, original posting date not specified. The September 23 advisory panel will vote separately on reasonable assurance of safety, effectiveness, and whether benefits outweigh risks. Its recommendation is nonbinding, not marketing approval. FDA meeting and package; full notes.

Sponsor topline announcement. Following 21 weeks of weekly induction, every-other-week and monthly injections preserved more of the initial weight loss over 12 weeks than withdrawal to placebo. Viking September 22 maintenance topline; full notes.

Trial-registry update. The current record resolves the old not-yet-recruiting discrepancy for CBL-514's pivotal abdominal-fat trial. SUPREME-01 / CBL-0301 (NCT07140939); full notes.

Peer-reviewed descriptive secondary-endpoint analysis within randomized trial. All-cancer episode sensitivity was 37.2%, 27.1% and 26.7% in annual rounds 1–3, with PPV 58.0%, 50.4% and 45.8%. Specificity remained about 99.5–99.6%. Lower repeat-round detection concerns the changing prevalent/incident cancer pool, not evidence of technical deterioration. NHS-Galleri original full report, published September 22; full notes.

Peer-reviewed prospective single-arm interventional study. PPV 60.3% (173/287), specificity99.64%, all-cancer episode sensitivity39.3%, 12-cancer subgroup69.8%; median diagnostic resolution48 days. Core values match the existing conference note. PATHFINDER 2 full publication, September22; full notes.

Sponsor topline announcement. Roche reports glycemic and weight reductions in 447 adults with type 2 diabetes and overweight/obesity. Placebo magnitudes, intervals, estimand and arm denominators withheld. June 24 registry still specifies week-36 co-primary endpoints, whereas the release calls them week-48: unresolved source discrepancy. On-treatment normal HbA1c is not diabetes remission. Roche September 22 topline; full notes.

Sponsor conference announcement. Moderna identifies ESMO LBA1 as the detailed phase 3 presentation for intismeran plus pembrolizumab in resected stage IIB–IV melanoma. Moderna September 21 announcement; full notes.

Sponsor preliminary phase 1/2 report. Three anti-AAV-antibody-negative patients with relapsed/refractory ALL achieved MRD-negative complete responses after VNX-101; the broader SENTRY-CD19 study has dosed nine patients with several CD19-positive malignancies. Vironexis September 21 release; full notes.

Sponsor-reported FDA filing action. FDA accepted Insmed’s supplemental application for full approval and broader MAC lung-disease use, with a January 28, 2027 action target. Insmed September 21 release; full notes.

Sponsor topline announcement. REIMAGINE 5 reported greater weight reduction and noninferior HbA1c reduction with CagriSema 1.0/1.0 mg versus tirzepatide 5 mg. Novo September 21 release; full notes.

Sponsor topline announcement. The lower-dose regimen reported approximately 21% weight reduction over 68 weeks in adults without diabetes. Novo September 21 release; full notes.

Sponsor topline announcement. Novo reported improved pain ratings in type 2 diabetes with painful peripheral neuropathy, and plans Phase 3 neuropathy trials across its portfolio during 2027. Novo Diabetes CMD, slide 10; full notes.

Sponsor topline announcement. Caliway's small placebo-controlled trial met its primary pain endpoint; the previously forecast September readout has occurred. Caliway September 21 Dercum readout; full notes.

Regulatory action announced by sponsor. Menarini and NewAmsterdam announced European Commission authorization of Ubeslo (obicetrapib 10 mg) and Evlarco (obicetrapib 10 mg/ezetimibe 10 mg) for primary hypercholesterolaemia or mixed dyslipidaemia. Menarini September 21 authorization announcement; full notes.

Sponsor conference poster and release; randomized phase 3, not yet a full peer-reviewed report. Study 451 supports an acute-mania indication, with substantial symptom improvement over three weeks; the original poster also reports serious events and a death. The original poster reports two serious adverse events and one death in the active arm; causation was not established. J&J September 21 release; full notes.

Peer-reviewed open-label, single-arm pilot. A 14-person bipolar II depression study adds preliminary efficacy and important mood-switching/suicidality observations. The uncontrolled design and psychiatric adverse events limit any efficacy or safety claim. Downey et al., Journal of Clinical Psychiatry, September 21; full notes.

sponsor presentation announcement; older topline context separately labeled. Q32 will present additional 36-week findings and initial 16-week off-drug observations from SIGNAL-AA Part B at EADV. The announcement supplies no new numerical result. September 21 presentation announcement; full notes.

Human first-in-human randomized crossover preprint; not peer-reviewed. N 10 MDD, n 9 completed both; amygdala FUS vs active-control somatosensory FUS did not differ on symptom improvement. More AEs with amygdala sonication, p=.028; 1 clinical worsening required monitoring, no SAEs. Primary preprint abstract; full notes.

Recovered recent randomized phase 2 human trial registration. AV-1959R will be studied in 160 cognitively unimpaired adults with preclinical Alzheimer disease. Original registry; full notes.

FDA approval and randomized trial subgroup. Inluriyo plus Verzenio is approved after endocrine therapy for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. Overall survival remained immature (35% deaths). The approved combination population is narrower than the whole study. September 18 approval recovered during this overlap search. FDA imlunestrant combination approval; full notes.

Peer-reviewed open-label randomized trial. A 14-hospital Chinese trial randomized 2,702 adults to seven-locus pharmacogenomic guidance or usual treatment for four weeks. Unblinded care and assessment, baseline medication imbalance and more frequent treatment changes/intensification complicate attribution to genetic matching. Short follow-up, selected Han Chinese population and no clinical cardiovascular outcomes limit applicability; no trial registration was located in the paper. Primary pharmacogenomic hypertension trial; full notes.

Trial-registry update. A newly appraised C-CAR168 protocol plans safety and disability-progression assessments in refractory progressive MS. It remains not yet recruiting; lymphodepletion and uncontrolled design limit what future responses could establish. ClinicalTrials.gov · NCT07825389; full notes.

Sponsor development milestone. The final visit is complete in the phase 3 Gorlin syndrome study of topical patidegib. Results remain blinded; the sponsor forecasts topline in late November 2026. Sol-Gel, September 17; full notes.

Regulatory action; September 2026 U.S. prescribing information verified. The September label adds CKD associated with type 1 diabetes. Approval relies on albuminuria reduction with inferred kidney-event benefit; this is not a new trial directly proving dialysis prevention. Hyperkalemia remains an important risk. Bayer U.S. announcement; full notes.

Safety correction to earlier sponsor report. Safety correction to the September 2 pilot: the current sponsor report includes one myocardial infarction in the multi-therapy arm, assessed as possibly associated with physical activity. The event date is unknown; no causal attribution to a drug is established. AgelessRx current pilot report; full notes.

New formal human trial registration; no results. Cilcare registered REACT, a phase 1b/2a study of transtympanic Paliroden (CIL001). REACT original ClinicalTrials.gov record; full notes.

Investigator interim adaptive-trial decision. The metformin arm stopped September 15; alpha-lipoic acid passed the interim checkpoint and continues to the next stage. This is progressive-MS evidence, not a healthy-aging or lifespan trial. Numerical comparative effects were not reported in the reviewed summary. Passing the checkpoint does not establish alpha-lipoic acid clinical benefit. OCTOPUS interim decision; full notes.

Sponsor-reported trial authorization; recovered overlap finding. SASPiPhi reported MHRA authorization for a first-in-human phase 1b/2a engineered-phage study in cystic fibrosis with Pseudomonas lung infection. Authorization explicitly remains conditional on funding, insurance and final HRA authorization. Registry redirected to a holding page; design, recruitment and start date were not independently verified. The September 17 announcement is newly appraised, not a September 29 trial launch. SASPiPhi September 17 release; full notes.

Sponsor announcement of planned human study; no in-patient hair efficacy. Rubedo forecasts an October 2026 androgenetic-alopecia trial and first-half 2027 early data. Its reported hair growth derives from human follicles outside the body, not treated patients. Original sponsor release; full notes.

New phase 2 trial registration. Randomized timing comparison with symptoms and function still prospective. ClinicalTrials.gov · NCT07822607; full notes.

Peer-reviewed observational abstract; full methods unavailable. Symptom and sleep scores improved, but sleepiness prevalence did not. journals.sagepub.com · article; full notes.

Sponsor topline; randomized phase 3. Mosunetuzumab plus lenalidomide improved progression-free survival versus rituximab plus lenalidomide in previously treated follicular lymphoma, according to sponsor topline. Numerical effects, mature overall survival and detailed safety remain pending. Genentech, September 16; full notes.

Peer-reviewed randomized noninferiority trial. For selected surgically managed orthopedic infections with local antibiotic carriers, a short systemic course was noninferior to a longer course. Open-label treatment with blinded endpoint adjudication. Do not extrapolate to infections without implanted local antibiotics or to all orthopedic/hardware infections. September 16 publication recovered in this overlap search, not a September 27 result. Short or Long Antibiotic Regimens in Orthopaedics, PubMed; full notes.

Sponsor interim topline. Early sponsor-reported dual PCSK9/APOC3 RNAi data show substantial lipid-marker lowering. Small interim cohorts, incomplete dose/time-point denominators and no cardiovascular-event evidence limit interpretation. Arrowhead September 15 release; full notes.

Official sponsor conference schedule. Eloralintide plus tirzepatide phase 2 results are scheduled for September 30 at EASD. This is a disclosure date; the announcement supplies no new numerical combination efficacy or safety results. Lilly EASD announcement; full notes.

trial-registry update. The planned phase 2/3 AWAKEN trial targets 600 men and is still listed not yet recruiting. Primary completion is estimated for December 2027; registration is neither new efficacy evidence nor confirmation of first dosing. AWAKEN record; full notes.

Sponsor topline; overlap-window finding. Seabreeze STAT Asthma missed statistical significance on 28-day treatment failure despite a reported 66% relative reduction (p=.153). The day-7 lung-function secondary endpoint improved. Connect September 15 release; full notes.

Sponsor trial-discontinuation announcement. Following independent DMC advice, Boehringer discontinued the vicadrostat-plus-empagliflozin trial because accumulating data did not support a meaningful expectation of benefit on its primary composite. Boehringer September 15 discontinuation; full notes.

Sponsor topline announcement in SEC filing. In 428 adults with primary IgA nephropathy, atacicept's final analysis reported slower filtration decline and fewer composite kidney-progression events. Vera September 15 SEC press-release exhibit; full notes.

Recovered recent randomized phase 1 human trial registration. The 32-person study tests six supervised doses during one menstrual cycle, primarily for safety and tolerability. Original registry; full notes.

Sponsor commercial forecast with FDA approval cross-check; older source newly recovered. Merz forecasts October 14 availability for Belotero Volume (+) and December 1 for Intense (+). Those dates are not new approval dates or proof that providers already stock them. Original Merz announcement; full notes.

sponsor_topline_randomized_phase3. Panorama met its phase 3 generalized-anxiety endpoint at 12 weeks. These are sponsor topline findings with detailed results pending; DT120 remains investigational. September 14 sponsor result; full notes.

Original sponsor release. FDA Breakthrough Therapy designation adds regulatory support for adjunctive phage treatment of complicated staphylococcal bloodstream infections. This is neither approval nor a new efficacy result. September 14 designation; full notes.

Original sponsor conference report. Enhertu improved progression-free survival in untreated HER2-mutant lung cancer. Overall survival remains immature with no demonstrated benefit, and four fatal interstitial-lung-disease events were reported; this first-line use remains investigational. Sponsor report, 2026-09-14; full notes.

Original sponsor report; linked journal article access failed. Exploratory eight-year follow-up supports sustained survival benefit after adjuvant osimertinib, with incomplete additional survival follow-up for 127 patients. This is a later analysis of the existing trial. Sponsor report, 2026-09-14; full notes.

Sponsor topline. The oral peripheral CB1 inverse agonist adds a non-incretin obesity program to the broader metabolic watch. Short phase 1b study, no uncertainty intervals or long-term outcomes; sponsor GLP-1 comparisons are cross-trial, not head-to-head. Do not label CRB-913 an incretin or add it to hormone-mimetic plots without explicit scope change. Corbus September14 release; full notes.

Peer-reviewed randomized human trial. A 44-person randomized inflammatory-myopathy trial favored IVIG added to prednisone at 12 weeks. One asymptomatic deep-vein thrombosis occurred with IVIG; this is disease-specific evidence, not healthy muscle building. JAMA Neurology September14 publication; full notes.

sponsor topline randomized phase 2. The phase 2 study did not significantly improve Day 5 depression scores versus placebo. Detailed effects and safety rates remain pending; the sponsor has not announced program discontinuation. September 14 issuer release filed with SEC; full notes.

Regulatory action. Apitegromab is now approved for SMA in patients aged at least two receiving SMN2-targeted treatment; obesity-related muscle preservation remains investigational. FDA action; full notes.

Original sponsor release. Camizestrant missed SERENA-4’s primary progression-free-survival endpoint. This upfront first-line result concerns a different strategy from switching after an emerging ESR1 mutation in SERENA-6. Sponsor report, 2026-09-11; full notes.

Recovered trial-registration addition. BAARD (NCT07810738) is a newly identified September 9 registration, not an October launch. Washington University plans a masked randomized phase 2 study of 300 adults aged 60 or older with treatment-resistant major depression. A biotype/computer predictive model selects aripiprazole or bupropion augmentation in one group; the comparison group receives a randomly selected one of those same medicines. ClinicalTrials.gov · NCT07810738; full notes.

Sponsor-reported regulatory milestone; recovered watchlist addition. Nanoscope announced September 9 that FDA accepted for review its BLA for MOGENRY (sonpiretigene isteparvovec; MCO-010) for retinitis pigmentosa with severe vision loss. This is a gene-agnostic optogenetic therapy in an inherited retinal disease. Acceptance is not approval or routine U.S. availability. The release did not state an FDA action date. Supporting RESTORE (NCT04945772) enrolled 27 participants in a randomized sham-controlled trial; the registry labels it phase 2, while the sponsor describes phase 2b/3. PR Newswire · news release; full notes.

Original sponsor release and registry. All three afimetoran doses met the phase 2 lupus response endpoint, according to the sponsor. Response percentages and detailed safety tables remain pending; the drug is investigational. Beeline, September 9; full notes.

sponsor_report_of_peer_reviewed_publication. The FirstLight and RadiantLight phase 3 narcolepsy trials are now published. This adds evidence to an existing approval; U.S. launch remains forecast by November pending DEA scheduling. September 9 publication announcement; full notes.

Peer-reviewed randomized phase 1/2a study. Inhaled siRNA established early target engagement and safety observations, with transient lung-diffusion changes at higher doses. It has not established clinical asthma benefit. Nature Medicine, September 9; full notes.

sponsor topline open-label extension. The sponsor reports improvement through week 52 in a selected open-label extension allowing additional psilocybin doses. Attrition and redosing mean this is not randomized evidence that one dose lasts a year. Compass September 9 extension topline; full notes.

Sponsor regulatory announcement. Sponsor reported MHRA application acceptance and EMA submission planned later September; no approval established. September company announcement; full notes.

Sponsor topline — negative result. Del-desiran missed HARBOR’s primary hand-myotonia endpoint in myotonic dystrophy type 1. Secondary signals and the future development path remain under review. Sponsor report; full notes.

Peer-reviewed abstract retrieved via Europe PMC; original sponsor release. Published phase 3 trials found fewer COPD exacerbations in the primary former-smoker population. FDA Priority Review is sponsor-confirmed, with a Q1 2027 decision forecast; approval is not established. Regulatory announcement; NEJM article, September 8; full notes.

Original sponsor release. The sponsor reports improved survival from tarlatamab plus durvalumab maintenance in extensive-stage small-cell lung cancer. Effect sizes and full safety results remain unpublished; combination approval is not established. Sponsor report, 2026-09-08; full notes.

sponsor_trial_initiation_with_registry. QUELL-DME has begun studying oral BGE102 for diabetic macular edema. The phase 2 trial has no efficacy results yet; a 2027 readout remains a forecast. Sponsor announcement; full notes.

Peer-reviewed randomized trial; accepted early article. Among 1,152 analyzed couples, non-invasive PGT-A did not significantly improve ongoing pregnancy or live birth after the first transfer. This tests DNA in embryo culture medium, distinct from biopsy PGT-A and polygenic embryo selection. Original trial, September 8; full notes.

Sponsor topline — detailed results pending. STEP Young met its pediatric BMI endpoint; full numerical results and detailed safety remain pending. The 40.4% headline is a BMI-category response, not weight loss. Sponsor topline; full notes.

Peer-reviewed randomized trial; primary abstract reviewed. In mostly vitamin-D-replete older adults, neither supplemental dose prevented fractures; 1,600 IU/day increased fractures during treatment. The findings do not answer treatment of established deficiency. Original abstract, September 7; full notes.

Peer-reviewed randomized human study. A single-center randomized study found better six-month clinician-rated scars after reconstructive grafting; recurrence did not significantly differ. This is not evidence of cosmetic scar erasure. Original open-access paper; full notes.

Sponsor announcement — negative development. BNT122-01 colorectal vaccine monotherapy trial terminated after futility and numerical OS imbalance; pancreatic combination study unaffected. August 28 sponsor statement; full notes.

Peer-reviewed randomized human study. Small randomized tray-schedule study found more refinements and no shorter overall treatment Primary paper; full notes.

Sponsor topline — full numerical data pending. INTerpath-001 intismeran plus pembrolizumab met RFS and DMFS endpoints; full numerical data pending. August 19 announcement; full notes.

Sponsor regulatory announcement. Japan phase IIa trial-notification review completed; efficacy and readout date remain unverified Dated sponsor announcement; full notes.